Characterizing novel beta-lactamases from metagenomic samples: insights into the evolution of antimicrobial resistance from the environment towards human-associated pathogens
Active Project Grant Awarded Last action
- Award ID
- R01AI160371
- Recipient
-
Ubatec SA UEI ZY8ZEHEYJ3M6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $757,662
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 82% complete
- Place of performance
- Argentina
Award details come from USAspending.gov.
Description
- Abstract
- SS-lactamases are the most widespread resistance mechanism to SS-lactam antibiotics. Of particular concern are a group of SS-lactamases known as carbapenemases, named for their ability to destroy our newest SS-lactam antibiotics, the carbapenems. The rise of carbapenem resistance is a recent global trend that has resulted in pan-national fear. An interesting approach to understand carbapenem resistance and how IT evolves is through quantitative analysis of non-pathogenic microorganisms found in the environment. Analysis of these microorganisms offers the intriguing possibility of predicting how antibiotic resistance may evolve and provides clinicians with an "early warning" system for the advent of novel resistance mechanisms in pathogenic bacteria. Previous research has shown that the soil is an excellent repository for many SS-lactamases, especially carbapenemases. The main part of the project will be the study of a collection of metagenome-origin SS-lactamases isolated from alaskan soil, named LRA (for "SS-lactam resistance from alaska"). This metagenomic approach will be expanded and applied to the analysis of soil samples from antarctica to identify SS-lactamase-mediated resistance in different isolated regions. Identified environmental SS-lactamases will be characterized using a multi-pronged approach involving phenotypic, molecular, biochemical and structural techniques. Specifically, results from this comprehensive analysis will allow US to assess the evolutionary routes of SS-lactamases found among clinical pathogens that plague human health today, and to evaluate novel niches of potentially unexplored genes that could be recruited by these pathogens.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $119,871 | |
| Amendment | $127,235 | |
| Amendment | $128,258 | |
| Amendment | $126,842 | |
| Amendment | $127,728 | |
| Original award | $127,728 |
Quick answers
Who received award R01AI160371?
R01AI160371 was awarded to Ubatec SA by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 21, 2022.
How much is award R01AI160371 worth?
$757,662 has been obligated on R01AI160371.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award